Cytotoxic Flashcards
Which mediations are used to in N&V ?
• 5-TH3 antagonist
• Substance P antagonist (acts on vomiting centre and CTZ)
• dexomethasone
• dopamine antagonist
High emetogenic risk (90%) meds?
• carmustine
• carboplatin (> AMU)
• cisplatin
• cyclophosphamide (>1500)
• busulfan - oral
Moderate Emetogenic Risk (30-90%) meds?
• carboplatin (<AUC)
• cyclophophamide ( <1500)
• cyclophophamide - oral
• imatinib oral
• datinomycin
• methotrexate
Low emtogentic risk (10-30%) meds?
• docetaxel
• methotrexate
• axitinib - oral
How to manage high risk emetogenic - acute and delayed ?
Acute
• 5-HT3 antagonist +
• substance P antagonist +
• dethomethasone
Delayed
• continue dethomethasone - omit if corticosteroids are being used
How to manage mod risk emetogenic - acute and delayed
Acute
• 5-HT3 +
• dexomethasone
Delayed
• 5-HT3 OR Dexomesthasone
How to manage low risk emetogenic - acute and delayed
Acute
• dopamine antagonist OR
• domperidone
Delayed
• antiemetics are not required
What is breakthrough Emesis?
When patient experience N/V after after antiemetic prophylaxis treatment
How to treat breakthrough Emesis?
• lorazepam
• 5-HT3 antagonist
• dexamethasone
• dopamine antagonist
- prochloperazine
- domperidone
Anticipatory Emesis treatment
BZD
• lorazepam
• can also help relieve anxiety
• give orally
Radiation infused nausea & vomiting?
• GI tract is most sensitive to radiation
• uncontrolled can lead to delay or refusal of treatment.
Assessments for patient with N+V?
• intensity, duration and frequency of vomiting
• dehydration?
• nutritional status
• serum electrolyte imbalance
RINV - risk factors?
• area of treatment
• size of treatment area
• dose of radiation
How to manage high risk RINV?
5-HT3 antagonist + dexomethasone
How to manage medium risk of RINV ?
5-HT3 antagonist + optional - dexomethasone